Gut bacteria-produced exopolysaccharides (EPS) help regulate metabolism by modulating gut microbiota, promoting SCFA ...

BioAge Labs, Inc. (BIOA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jeffrey ...

Analyst Samantha Semenkow from Citi maintained a Hold rating on BioAge Labs, Inc. (BIOA – Research Report) and keeping the price target at ...

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...

We hypothesised that colonic delivery of propionate would increase peptide YY (PYY) and glucagon like peptide-1 ... all subjects to the nearest 0.1 kg (Tanita BC-418MA) while subjects were wearing ...

Objective—Glucagon-like peptide 1 (GLP-1) exerts beneficial antidiabetic actions via effects on pancreatic β- and α-cells. Previous studies have focused on the improvements in β-cell function ...

You’ve probably thought about taking charge of your health and being more proactive. Whether you’re overweight, are struggling to build muscle, or have lost your “spark” as your testosterone levels ...

The composition of human milk microbiota may be influenced ... For example, SCFAs produced by microbes regulate the expression and secretion of glucagon-like peptide-1 (GLP-1) through the free fatty ...

With with GLP-1 drugs, gastrointestinal issues, such as nausea, vomiting, constipation, and gastroesophageal reflux disease, ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...